Pexmetinib suppresses osteoclast formation and breast cancer induced osteolysis via P38/STAT3 signal pathway

Breast cancer metastases to the bone can lead to a series of bone-related events that seriously affect the quality of life. Pexmetinib, a novel p38 mitogen-activated protein kinase (p38) inhibitor that has been evaluated in phase I clinical trials for myelodysplastic syndrome, but the effects of Pex...

Descripción completa

Detalles Bibliográficos
Autores principales: Jie, Zhiwei, Wang, Shiyu, Ma, Qingliang, Shen, Yang, Zhao, Xiangde, Yu, Hejun, Xie, Ziang, Jiang, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253705/
https://www.ncbi.nlm.nih.gov/pubmed/35800294
http://dx.doi.org/10.1016/j.jbo.2022.100439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253705/
https://www.ncbi.nlm.nih.gov/pubmed/35800294
http://dx.doi.org/10.1016/j.jbo.2022.100439

Ejemplares similares